SunTrust analyst Edward Nash raised his price target on uniQure to $76 after the company disclosed plans last week to present 24-week data from its ongoing Phase IIb study of AMT-061 in hemophilia B on May 10th . The analyst believes that the pre-clinical data should provide “additional validation” to uniQure’s “technology platform and research engine,” keeping his Buy rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.